Travere Therapeutics presents new data at ASN Kidney Week 2026 supporting FILSPARI (sparsentan) as a foundational treatment for IgA nephropathy and focal segmental glomerulosclerosis (FSGS). The Phase 2 SPARTAN Study shows high rates of complete proteinuria remission and potential benefits for patients without nephrotic syndrome.
Over two years, patients experienced ... Travere Therapeutics. "In FSGS, the DUPLEX analysis adds to the evidence supporting the use of FILSPARI for patients without nephrotic syndrome, with higher complete proteinuria remission rates and lower observed rates of kidney failure compared to irbesartan. Together, these data reinforce the clinical value of FILSPARI across two rare, progressive kidney diseases.” · The final data readout from the Phase 2 SPARTAN Study, an open-label trial evaluating ... Over two years, patients experienced high rates of complete proteinuria remission and near physiologic eGFR decline, highlighting the potential for an oral, non-immunosuppressive therapy to address both key treatment goals early in the disease course," said Jula Inrig, M.D., chief medical officer of Travere Therapeutics. "In FSGS, the DUPLEX analysis adds to the evidence supporting the use of FILSPARI for patients without nephrotic syndrome, with higher complete proteinuria remission rates and lower observed rates of kidney failure compared to irbesartan. Together, these data reinforce the cli SAN DIEGO--(BUSINESS WIRE)--Oct 2, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American … Incident Patients With IgA Nephropathy (IgAN) Demonstrated Stable eGFR With First-Line Sparsentan (SPAR) Over 2 Years in the SPARTAN Final Analysis Poster: TH-PO0453 Poster session: Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - IgAN Exhibit Hall A; October 22, 10:00 a.m.-12:00 p.m. MDT · Spatial transcriptomics reveals sparsentan-associated remodelling of complement-active renal niches in IgA Nephropathy Abstract: SA-OR048 Oral Abstract Session: Glomerular Diseases: Clinical Trial Results Mile High Ballroom 4A; October 24, 4:30 p.m.-6:00 p.m. Sparsentan (SPAR) vs Irbesartan (IRB) in Patients (Pts) With Focal Segmental Glomerulosclerosis (FSGS) Without Nephrotic Syndrome (NS) in the Phase 3 DUPLEX Trial Poster: FR-PO0645 Poster session: Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research – ANCA/FSGS Exhibit Hall A; October 23, 10:00 a.m.-12:00 p.m.
Original title: “Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026 | Dorchester Banner”